OBJECTIVE: To assess the influence of weight reduction therapy on serum osteoprotegerin (OPG) concentration in obese patients and compare these results with normal-weight controls. RESEARCH METHODS AND PROCEDURES: Forty-three obese women (BMI, 36.7 +/- 4.1 kg/m2; mean age, 50.1 +/- 4.5 years) were studied. The control group consisted of 19 normal-weight women (BMI, 24.2 +/- 2.1 kg/m2; mean age, 53.8 +/- 5.2 years). In all patients, serum concentrations of OPG, C telopeptide of type I collagen containing the cross-linking site (CTX), osteocalcin, parathormone, 25-(OH)-D3 (vitamin D), and total calcium and phosphorus were assessed before and after a 3-month weight reduction therapy. RESULTS: In obese subjects, serum concentrations of OPG, 25-(OH)-D3, osteocalcin, total calcium, and phosphorus were significantly lower, and serum concentration of parathormone was significantly higher, before weight reduction therapy in comparison with normal-weight controls. After weight reduction, a significantly higher serum concentration of 25-(OH)-D3 and CTX and significantly lower concentration of OPG were found. DISCUSSION: Serum concentration of OPG was significantly lower in obese patients in comparison with normal-weight controls. Weight reduction therapy resulted in further decrease in OPG serum concentrations. Therefore, OPG cannot be treated as a protective factor from bone loss in obese patients.
OBJECTIVE: To assess the influence of weight reduction therapy on serum osteoprotegerin (OPG) concentration in obesepatients and compare these results with normal-weight controls. RESEARCH METHODS AND PROCEDURES: Forty-three obesewomen (BMI, 36.7 +/- 4.1 kg/m2; mean age, 50.1 +/- 4.5 years) were studied. The control group consisted of 19 normal-weight women (BMI, 24.2 +/- 2.1 kg/m2; mean age, 53.8 +/- 5.2 years). In all patients, serum concentrations of OPG, C telopeptide of type I collagen containing the cross-linking site (CTX), osteocalcin, parathormone, 25-(OH)-D3 (vitamin D), and total calcium and phosphorus were assessed before and after a 3-month weight reduction therapy. RESULTS: In obese subjects, serum concentrations of OPG, 25-(OH)-D3, osteocalcin, total calcium, and phosphorus were significantly lower, and serum concentration of parathormone was significantly higher, before weight reduction therapy in comparison with normal-weight controls. After weight reduction, a significantly higher serum concentration of 25-(OH)-D3 and CTX and significantly lower concentration of OPG were found. DISCUSSION: Serum concentration of OPG was significantly lower in obesepatients in comparison with normal-weight controls. Weight reduction therapy resulted in further decrease in OPG serum concentrations. Therefore, OPG cannot be treated as a protective factor from bone loss in obesepatients.
Authors: Caitlin Mason; Liren Xiao; Ikuyo Imayama; Catherine R Duggan; Carolyn Bain; Karen E Foster-Schubert; Angela Kong; Kristin L Campbell; Ching-Yun Wang; Marian L Neuhouser; Li Li; Robert W Jeffery; Kim Robien; Catherine M Alfano; George L Blackburn; Anne McTiernan Journal: Am J Clin Nutr Date: 2011-05-25 Impact factor: 7.045
Authors: Jeanne M McCaffery; George D Papandonatos; Gordon S Huggins; Inga Peter; Bahar Erar; Steven E Kahn; William C Knowler; Edward W Lipkin; Abbas E Kitabchi; Lynne E Wagenknecht; Rena R Wing Journal: Hum Hered Date: 2013-09-27 Impact factor: 0.444
Authors: P S Hinton; R S Rector; M A Linden; S O Warner; K C Dellsperger; A Chockalingam; A T Whaley-Connell; Y Liu; T R Thomas Journal: Eur J Clin Nutr Date: 2011-12-21 Impact factor: 4.016